RxDoctor Payments DataLook up a doctor →

Tiffany Sipe

Family · Knoxville, TNNPI 1174848303

Payments from drug & device makers

$86,566in general payments, 2019–2025

Across 1,151 payments — averaging $75.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$47K
  • Daiichi Sankyo Inc.$13K
  • Regeneron Healthcare Solutions, Inc.$8K
  • AstraZeneca$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$1K
  • plus $14K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)116$47,328
Daiichi Sankyo Inc.76$13,178
Regeneron Healthcare Solutions, Inc.35$7,962
AstraZeneca(2 entities)70$1,371
E.r. Squibb & Sons, L.L.C.102$1,361
Novartis62$1,215
Merck47$918
Gilead(2 entities)45$883
Karyopharm Therapeutics Inc.9$837
Incyte Corporation41$761
Bristol Myers Squibb63$748
Amgen30$709
Pfizer37$634
Epizyme, Inc.5$611
Astellas Pharma US Inc33$601
Seagen Inc.32$594
GSK34$520
Sanofi27$467
Genentech USA, Inc.29$446
Exelixis Inc.11$349
Bayer19$340
Eisai Inc.20$327
Lilly USA, LLC18$327
Puma Biotechnology, Inc.15$283
Takeda Pharmaceuticals U.S.A., Inc.15$275
Myriad Genetic Laboratories, Inc.7$249
Sobi, Inc11$226
AbbVie12$216
EMD Serono, Inc.9$183
AVEO Pharmaceuticals, Inc.6$173
Pharmacyclics LLC, An Abbvie Company12$166
Ipsen Biopharmaceuticals, Inc7$159
Caris MPI, Inc.4$152
Iovance Biotherapeutics, Inc.2$145
Rigel Pharmaceuticals, Inc.5$140
Stemline Therapeutics Inc.3$140
Beigene USA, Inc.7$135
Array Biopharma Inc8$127
Tersera Therapeutics LLC6$115
Boehringer Ingelheim6$97
Adaptive Biotechnologies Corporation3$93
Genmab U.S., Inc.4$82
ADC Therapeutics America, Inc.4$80
Taiho Oncology, Inc.4$77
Mirati Therapeutics, Inc.3$67
Janssen Scientific Affairs, LLC1$62
Morphosys, US Inc.3$47
Pharmaessentia USA Corporation2$47
Myovant Sciences Inc.3$45
Macrogenics, Inc.2$44
Deciphera Pharmaceuticals Inc.2$44
Pharmacosmos Therapeutics Inc.2$35
Coherus Oncology, Inc.2$34
Jazz Pharmaceuticals Inc.2$30
Acrotech Biopharma Inc.2$27
Corcept Therapeutics1$25
Clovis Oncology, Inc.2$24
Kyowa Kirin, Inc.1$24
Servier Pharmaceuticals LLC1$23
G1 Therapeutics, Inc.1$22

How this compares

$86,566 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee →

Medicare billing

Part B allowed, 2024
$39,253
Medicare patients
56
Services billed
3,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Knoxville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →